BNP/PUT/ELI LILLY & CO/900/0.1/16.01.26 Stock

BNP/PUT/ELI LILLY & CO/900/0.1/16.01.26 Share Price

DE000PC7ZJT1

Real-time Boerse Frankfurt Warrants 02:20:36 27/06/2024 pm IST
11.06 ^EUR	-0.81%

Current month	-24.10%
1 month	-26.55%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart BNP/PUT/ELI LILLY & CO/900/0.1/16.01.26

Latest news about ELI LILLY AND COMPANY

Augustine Therapeutics N.V. announced that it expects to receive funding from a group of investors	26/06	CI
Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls	25/06	MT
Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens	25/06	DJ
Eli Lilly Teams Up With OpenAI to Develop Antimicrobials for Drug-Resistant Bacteria	25/06	MT

More news

Quotes 5-day view

Date	Price	Change
27/24/27	11.06	-0.81%
26/24/26	11.15	+1.00%
25/24/25	11.04	-3.92%
24/24/24	11.49	-3.77%
21/24/21	11.94	+0.17%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 02:20 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	ELI LILLY AND COMPANY
Issuer	BNP Paribas
WKN	PC7ZJT
ISIN	DE000PC7ZJT1
Date issued	09/04/2024
Strike	900 $
Maturity	16/01/2026 (569 Days)
Parity	10 : 1
Emission price	15.03 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	20.33 €
Lowest since issue	10.75 €
Delta	-0.38x
Omega	2.876
Premium	13.3x
Gearing	7.6x
Moneyness	0.9986
Difference Strike	-1.26 $
Difference Strike %	-0.14%
Spread	0.03 €
Spread %	0.27%
Theoretical value	11.07
Implied Volatility	32.76 %
Total Loss Probability	48.97 %
Intrinsic value	0.000000
Present value	11.07
Break even	781.70 €
Theta	-0.05x
Vega	0.39x
Rho	-0.44x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company